linsidomine has been researched along with Pulmonary Hypertension in 7 studies
linsidomine: RN given refers to parent cpd; structure
| Excerpt | Relevance | Reference |
|---|---|---|
| "The present study addressed whether combined treatment with a phosphodiesterase type 5 inhibitor, sildenafil, and a nitric oxide donor, molsidomine, prevents development of pulmonary hypertension in chronic hypoxic rats." | 7.73 | Lack of synergistic effect of molsidomine and sildenafil on development of pulmonary hypertension in chronic hypoxic rats. ( Andersen, CU; Mulvany, MJ; Simonsen, U, 2005) |
| "The present study addressed whether combined treatment with a phosphodiesterase type 5 inhibitor, sildenafil, and a nitric oxide donor, molsidomine, prevents development of pulmonary hypertension in chronic hypoxic rats." | 3.73 | Lack of synergistic effect of molsidomine and sildenafil on development of pulmonary hypertension in chronic hypoxic rats. ( Andersen, CU; Mulvany, MJ; Simonsen, U, 2005) |
| "In the treatment of pulmonary hypertension, this pathway is exogenously activated using inhaled NO or other pharmacological agents." | 1.37 | Attenuated vasodilatation in lambs with endogenous and exogenous activation of cGMP signaling: role of protein kinase G nitration. ( Aggarwal, S; Black, SM; Datar, S; Fineman, JR; Fratz, S; Gross, CM; Kalkan, G; Kumar, S; Oishi, P; Schreiber, C, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (14.29) | 18.2507 |
| 2000's | 5 (71.43) | 29.6817 |
| 2010's | 1 (14.29) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Aggarwal, S | 1 |
| Gross, CM | 1 |
| Kumar, S | 1 |
| Datar, S | 1 |
| Oishi, P | 1 |
| Kalkan, G | 1 |
| Schreiber, C | 1 |
| Fratz, S | 1 |
| Fineman, JR | 1 |
| Black, SM | 1 |
| Andersen, CU | 1 |
| Mulvany, MJ | 1 |
| Simonsen, U | 1 |
| Schwenke, DO | 1 |
| Pearson, JT | 1 |
| Tsuchimochi, H | 1 |
| Mori, H | 1 |
| Shirai, M | 1 |
| Girard, C | 1 |
| Neidecker, J | 1 |
| Laroux, MC | 1 |
| Champsaur, G | 1 |
| Estanove, S | 1 |
| Berkenbosch, JW | 2 |
| Baribeau, J | 2 |
| Perreault, T | 2 |
| Wanstall, JC | 1 |
| Gambino, A | 1 |
| Thomas, BJ | 1 |
| Barrington, KJ | 1 |
| Decker, ER | 1 |
| Wu, C | 1 |
| Brock, TA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase 1 Study of the Safety and Pharmacokinetics of Perioperative IV L-carnitine Administration in Patients With Congenital Heart Disease With Increased Pulmonary Blood Flow[NCT01825369] | Phase 1 | 0 participants (Actual) | Interventional | 2014-12-31 | Withdrawn (stopped due to Changes to cardiac surgery program) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
7 other studies available for linsidomine and Pulmonary Hypertension
| Article | Year |
|---|---|
Attenuated vasodilatation in lambs with endogenous and exogenous activation of cGMP signaling: role of protein kinase G nitration.
Topics: Administration, Inhalation; Animals; Animals, Newborn; Cells, Cultured; Cyclic GMP; Cyclic GMP-Depen | 2011 |
Lack of synergistic effect of molsidomine and sildenafil on development of pulmonary hypertension in chronic hypoxic rats.
Topics: Acetylcholine; Actins; Animals; Atrial Natriuretic Factor; Body Weight; Dose-Response Relationship, | 2005 |
Exogenous nitric oxide centrally enhances pulmonary reactivity in the normal and hypertensive rat.
Topics: Animals; Blood Pressure; Cardiac Output; Central Nervous System; Heart Rate; Hypertension, Pulmonary | 2005 |
Inhaled nitric oxide in pulmonary hypertension after total repair of total anomalous pulmonary venous return.
Topics: Administration, Inhalation; Antihypertensive Agents; Humans; Hypertension, Pulmonary; Infant; Male; | 1993 |
Decreased synthesis and vasodilation to nitric oxide in piglets with hypoxia-induced pulmonary hypertension.
Topics: Animals; Animals, Newborn; Arginine; Blood Vessels; Cyclic GMP; Hypertension, Pulmonary; Hypoxia; In | 2000 |
KRN2391: dual action on rat pulmonary artery and no loss of potency in pulmonary hypertension.
Topics: Adenosine Triphosphate; Animals; Cromakalim; Dose-Response Relationship, Drug; Enzyme Inhibitors; Gl | 2000 |
TBC3711, an ET(A) receptor antagonist, reduces neonatal hypoxia-induced pulmonary hypertension in piglets.
Topics: Animals; Animals, Newborn; Cell Line; Endothelin Receptor Antagonists; Endothelin-1; Humans; Hyperte | 2001 |